Company intelligence / Profile preview
ITBMed
Stockholm, Swedenitb-med.com ↗
- Ownership
- Private
- Employees
- ~45
- Development stage
- Other
01
Overview
Siplizumab has demonstrated the potential to allow organ transplant patients to discontinue all immunosuppressive drugs post-transplantation. In phase II trials it enabled successful transplants without lifelong immunosuppression. Recent phase II trials have been completed in renal transplantation with positive results reported as of December 2024.
- Therapeutic areas
- NeurologyEndocrinologyImmunologyNephrology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ITBMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITBMed.